NHS England to fund first ever treatment for children with rare muscle-wasting condition

NHS England will provide a promising new treatment which can prolong the lives of children with a rare genetic condition after negotiating a deal with the manufacturer. Nusinersen, also called Spinraza and made by Biogen, is the first treatment that targets the underlying cause of spinal muscular atrophy (SMA). The condition affects the nerves in […]